公开(公告)号：US20240182456A1

公开(公告)日：2024-06-06

申请号：US18554778

申请日：2022-04-11

申请人： Novartis AG

发明人： Martin ALLAN ,  Matthew CARSON ,  Thomas CAYA ,  Lara CZABANIUK ,  Ming QIAN ,  Daniel SMITH ,  Troy SMITH ,  Liansheng SU ,  Chung-Yeh WU ,  Lihua YANG ,  Chun ZHANG ,  Ping ZHANG ,  Xilin ZHOU

IPC分类号： C07D405/14 ,  C07D413/14 ,  C07D417/14

CPC分类号： C07D405/14 ,  C07D413/14 ,  C07D417/14

摘要： The present invention relates to compounds of formula (I) as activators of glucagon-like peptide 1 (GLP1) receptor for the treatment of obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, one or more diabetic complications, diabetic nephropathy, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hypertension, atherosclerosis, peripheral arterial disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease and neuropathy. Preferred compounds are e.g. 2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-imidazole derivatives and similar compounds, such as e.g. C-1, C-2, C-3, C-4 and other compounds.